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T
his decade has been disheartening to diabetes
scientists, not because their scientiﬁc discovery
and progress has slackened, but precisely the
opposite. Scientiﬁc journals are replete with new
basic and clinical research ﬁndings that ﬁre imaginations
about a better world for diabetic patients in the near
future. Funding the research has been the big problem.
Funds that are so critical to our progress on the road to
preventing and curing diabetes have been drastically con-
strained in the past several years by the National Institutes
of Health (NIH) and the American Diabetes Association
(ADA) because of budget shortfalls (wars and economic
downturns are expensive). The tragic irony is all too clear.
In a time of unparalleled accumulation of important new
knowledge and fresh scientiﬁc insights into prevention
and reversal of diabetes complications, the ﬁnancial re-
sources to take full advantage of recent leaps in knowl-
edge have been hard to come by.
With the NIH being essentially ﬂat-funded for the past
several years, the research community has lost ground to
inﬂation at this time of immense opportunity. While it is
impossible for ADA to take up all the slack, we recognize
we must protect our scientiﬁc future by maintaining
important ongoing research efforts. The ADA Research
Policy Committee (RPC) took steps this past year to
safeguard clinical translation of research and to protect
our most vulnerable research scientists. The latter are new
scientists just beginning research careers as well as estab-
lished scientists caught in the crossﬁre of budget shortfalls
as they attempt to renew their awarded grants. These steps
include the following: 1) the proportion of funds awarded
to human-based clinical projects was brought to parity
with funds awarded to basic science projects and 2)
support was prioritized for young scientists beginning
their careers and for meritorious established scientists
whose research programs have been compromised by
current economic circumstances. To do this, the RPC
reluctantly decided to temporarily discontinue new fund-
ing of established investigators already receiving over
$500,000 annually for their personal research.
Several other good things have evolved during this
important decision making. First, the RPC is constructing
a new strategic plan for its funding policies and will use it
for future decisions. The scientiﬁc vision inherent in this
plan will position the RPC to formulate responses to future
challenges in a timely and proactive manner. Second, the
ADA Executive Committee had an eye-opening experience
watching the struggles of ADA-funded scientists and
resolved to increase ADA research funding signiﬁcantly.
While the ﬁnal dollar amounts are still being hammered
out by the Board of Directors, the overall ADA strategic
plan written in 2008 is clearly committed to increasing the
current total ADA revenue of $233 million to $300 million
in the year 2011. If this plan is successful, this 29%
increase in revenue would result in at least a compara-
ble increase in research funding by 2011. The ADA
strategic plan also commits to maintaining its percentile
funding of research applications by 2011 to a level that
exceeds the prevailing funding percentile of NIH.
All that I have written above was composed before the
very recent dramatic falls in stock market values across
the globe. It is impossible to know where things will be in
January, when the publication process is ﬁnished and this
editorial sees the light of day. Clearly, the current ﬁnancial
gyrations will impact the ability of ADA to raise and even
sustain current contributions to research. Nonetheless, it
is reasonable to believe that as markets recover and as a
new administration is installed in the White House in 2009,
hope is justiﬁed that funding for all NIH-funded research
will eventually be restored to reasonable levels. History
and conventional wisdom tell us that failed markets, and
all that they affect in society, will eventually recover. The
message is to take heart, hold on a bit tighter and even
longer, and anticipate better times in the future. In the
meantime, ADA will conduct its business of supporting
clinical and basic support of research designed to conquer
diabetes to the best of its ability, all the while ﬁrmly
believing that failure is not an option.
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